SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?


To: Joe Copia who wrote (10362)8/29/2002 5:26:33 PM
From: StockDung  Read Replies (1) | Respond to of 19428
 
jOE, IS THIS THE SAME GUY?->Isaac Nussen 216.239.51.100



To: Joe Copia who wrote (10362)8/29/2002 5:42:17 PM
From: StockDung  Read Replies (1) | Respond to of 19428
 
.FEATURE-State regulators forge ahead on Wall St probes

By Per Jebsen

NEW YORK, Aug 29 (Reuters) - Regulators from more than 40 states are sifting through mounds of Wall Street's e-mails, employee evaluations and other internal documents, dissecting the role of stock analysts in the technology and telecom bubble.

They are hoping that the documents will provide a window into the analysts' activities, and whether financial companies routinely used favorable stock recommendations to win lucrative investment banking business.

While loath to tip their hand, many regulators suggest action against Wall Street firms will materialize in the near future. The measures would resemble the New York attorney general's probe into and settlement with Merrill Lynch & Co. <MER.N> this spring.

In fact, some regulators say they favor similar public releases of potentially embarrassing material to enable class-action lawyers to seek redress on behalf of injured investors. They have plenty of material to work from.

"We're still looking at thousands and thousands of (pages of) documents," said Joe Borg, president of the North American Securities Administrators Association (NASAA) and Alabama's director of securities. "I might get 30,000 (pages of) documents one week ... we could be seeing literally millions of pages."

Most of the about 44 states involved in the Wall Street inquiry have formed into teams that each focus on a top investment bank.

Bear Stearns Cos. <BSC.N>, for instance, is being probed by New Jersey with support from Delaware, Hawaii, Maine, Pennsylvania and Vermont, according to Ryan Ushijima, Hawaii's commissioner of securities. Lehman Brothers <LEH.N> is being investigated by Alabama, with the assistance of Georgia, Indiana and Mississippi, said Alabama's Borg.

A steering committee of a dozen or so states, chaired by California, New Jersey and New York, is overseeing the probe. The states are traveling unfamiliar terrain in examining the inner workings of global powerhouses like Goldman Sachs <GS.N> and Morgan Stanley <MWD.N>, rather than their more traditional fare of broker boiler rooms and penny-stock fraud.

Yet regulators dismiss the suggestion they are trying to beat the Securities and Exchange Commission to the punch -- or that they want to impose industry rules apart from the Commission.

The SEC, along with the National Association of Securities Dealers and New York Stock Exchange, are Wall Street's traditional watchdogs. They were upstaged by New York's Merrill inquiry, and have launched their own inquiries into analysts' conflicts-of-interest. So too have federal prosecutors.

"I really wouldn't classify what we're doing as some kind of race against the other regulators," said Tanya Solov, Illinois' director of Illinois' securities department.

Rather, the states are holding regular teleconferences with the SEC, NASD and NYSE and, in any case, the inquiries may differ somewhat, Borg said.

"We're not on the same page but we're in the same book," he said.

New York's probe into Merrill, which led to the multi-state coalition now investigating Wall Street, drew sharp criticism from those members of Congress who had championed analyst reform. New York's inquiry intruded on the federal domain, they charged.

The state regulators are politically ambitious and lack the expertise to investigate or devise a durable solution for analysts' conflicts, said Jon Macey, a law professor at Cornell University. The SEC under Harvey Pitt is better suited to the task, he said.

Nonetheless, opposition to the states' role has faded somewhat. An attempt by Morgan Stanley's chief executive to reduce the states' investigative authority fizzled. Most states, moreover, have signed off on the Merrill settlement, or said they will.

New York is most likely among the states to be next to act because the Merrill inquiry gave it a 10-month head start, regulators say. New York has at its disposal a powerful legal tool, the Martin Act, that makes it easier than it would be under federal law to bring securities fraud cases.

Last Friday, AT&T Corp. <T.N> said it had received a subpoena from the New York attorney general's office related to its probe of Citigroup's <C.N> Salomon Smith Barney equity research division.

YEAR-LONG PROBE

The overall Wall Street probe may last a year or so, Alabama's Borg said. The states feel an obligation to quickly wrap up their inquiries to restore confidence in the markets, he said.

The regulators hedge on potential remedies. The Merrill settlement would serve as a road map, but each case may require its own particular solution, they say.

Some regulators favor airing investment banks' dirty document laundry to provide class-action lawyers with the evidence they need to make cases.

"The private bar is extremely important to the process," especially given the difficulty of establishing "causation" -- the degree to which investors relied on research advice, said Ralph Lambiase, Connecticut's director of securities.

Ultimately, firmer internal supervision may prove necessary, regulators say.

"The compliance department did not always have control and authority over the top producers and top analysts," a regulator said. "Right now compliance doesn't seem to have the proper stick ... they don't have the authority over them that they should."

Wall Street firms or analysts hoping for a break since everyone did it may be in for an unpleasant shock.

"Just because there has been a widespread policy or practice amongst the firms, that doesn't make the practice a correct one or a proper one," Illinois' Solov said.

(Per Jebsen, Wall Street Desk, (646) 223-6152))

08/29/02 14:17 ET



To: Joe Copia who wrote (10362)8/29/2002 6:06:24 PM
From: StockDung  Respond to of 19428
 
SEC raises Bristol inventory probe to formal review

By Ransdell Pierson

NEW YORK, Aug 29 (Reuters) - Bristol-Myers Squibb Co. <BMY.N> on Thursday said a U.S. Securities and Exchange Commission inquiry into how the firm convinced wholesalers last year to buy surplus amounts of its drugs has been elevated into a formal investigation.

The SEC move is the latest setback for the New York-based drug giant, whose earnings are reeling from the inventory problems, patent expirations on key drugs and its controversial $2 billion cancer-drug partnership with ImClone Systems Inc. <IMCL.O>

Earlier this month, Bristol-Myers said in a SEC regulatory filing that it was cooperating with an SEC inquiry that began in April, and that it might become a more formal investigation.

Industry analysts have expressed concern the firm may have artificially inflated its earnings last year by coaxing wholesalers to buy huge surpluses of diabetes treatment Glucophage and a half-dozen other medicines. It spurred the sales by announcing their prices were soon to be increased.

The surplus buying has hurt demand for the same drugs this year, contributing to an expected 50 percent decline in company earnings in 2002. It has also harmed the credibility Chief Executive Peter Dolan, who took the helm of the firm in mid-2001.

In its Aug. 14 SEC filing, Bristol-Myers also cautioned that it might have to restate its earnings results for last year if the SEC inventory inquiry is unfavorable.

Bristol-Myers reaffirmed on Thursday it believes its accounting treatment for the wholesaler buildup was "appropriate," and that it continues to cooperate with the SEC review.

Richard Lawrence, a pharmaceuticals analyst for Parker/Hunter Inc., said the full scope of the SEC investigation is not yet known.

BLAME GAME

Bristol-Myers deserves blame for failing to warn Wall Street last year how the wholesaler overstocking of its medicines might hurt earnings this year, waiting instead until April 2002 to send out its alarm, Lawrence said.

"They should have made these disclosures last year, when they had the information," Lawrence said.

But he said it would be improper for the SEC or any government agency to pass judgment on special incentives used by firms to promote sales.

"And it would also be inappropriate for the SEC to suggest that any company should restate earnings because of chosen sales incentives," Lawrence said.

Many industry analysts, including Barbara Ryan of Deutsche Bank Securities, have said Bristol-Myers and Dolan have lost their credibility because of the inventory snafu and other alleged oversights.

One of the biggest criticisms of the company has been its pact with ImClone to develop and market the tiny firm's experimental cancer drug Erbitux, the most expensive deal in history for a single biotech product.

The U.S. Food and Drug Administration shook investors in late December by refusing to review the marketing application for the medicine, citing questionable or missing clinical data.

ImClone CEO Samuel Waksal later resigned his post and has been charged with allegedly trying to sell ImClone shares before the bombshell negative FDA news was made public.

Shares of Bristol-Myers on Thursday closed down 77 cents, or 3.1 percent, to $24.29.

08/29/02 17:29 ET